nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisapride—CYP2C8—Levothyroxine—hypothyroidism	0.276	0.42	CbGbCtD
Cisapride—CYP2C8—Liotrix—hypothyroidism	0.27	0.41	CbGbCtD
Cisapride—CYP3A4—Levothyroxine—hypothyroidism	0.112	0.17	CbGbCtD
Cisapride—HTR4—adrenal cortex—hypothyroidism	0.0222	0.0697	CbGeAlD
Cisapride—HTR4—pituitary gland—hypothyroidism	0.018	0.0563	CbGeAlD
Cisapride—HTR2A—cerebellar cortex—hypothyroidism	0.0172	0.0539	CbGeAlD
Cisapride—HTR4—adrenal gland—hypothyroidism	0.016	0.0503	CbGeAlD
Cisapride—HTR3A—nerve—hypothyroidism	0.0156	0.049	CbGeAlD
Cisapride—CYP2C19—urine—hypothyroidism	0.0143	0.0449	CbGeAlD
Cisapride—CYP1A2—urine—hypothyroidism	0.0117	0.0367	CbGeAlD
Cisapride—CYP2C9—urine—hypothyroidism	0.0111	0.0348	CbGeAlD
Cisapride—DRD2—nerve—hypothyroidism	0.00956	0.03	CbGeAlD
Cisapride—HTR2A—urine—hypothyroidism	0.00914	0.0287	CbGeAlD
Cisapride—CYP3A4—urine—hypothyroidism	0.00846	0.0265	CbGeAlD
Cisapride—CYP2D6—urine—hypothyroidism	0.00833	0.0261	CbGeAlD
Cisapride—HTR2A—nerve—hypothyroidism	0.00631	0.0198	CbGeAlD
Cisapride—CYP3A7—liver—hypothyroidism	0.00479	0.015	CbGeAlD
Cisapride—HTR2B—adrenal cortex—hypothyroidism	0.00453	0.0142	CbGeAlD
Cisapride—HTR2B—heart—hypothyroidism	0.00439	0.0137	CbGeAlD
Cisapride—HTR3A—blood—hypothyroidism	0.00433	0.0136	CbGeAlD
Cisapride—HTR2B—cardiovascular system—hypothyroidism	0.00414	0.013	CbGeAlD
Cisapride—CYP3A7-CYP3A51P—liver—hypothyroidism	0.00407	0.0128	CbGeAlD
Cisapride—KCNH2—heart—hypothyroidism	0.0035	0.011	CbGeAlD
Cisapride—CYP2A6—liver—hypothyroidism	0.00333	0.0104	CbGeAlD
Cisapride—KCNH2—cardiovascular system—hypothyroidism	0.0033	0.0104	CbGeAlD
Cisapride—HTR2B—adrenal gland—hypothyroidism	0.00327	0.0103	CbGeAlD
Cisapride—HTR2B—blood—hypothyroidism	0.00327	0.0103	CbGeAlD
Cisapride—CYP2A6—cerebellum—hypothyroidism	0.00325	0.0102	CbGeAlD
Cisapride—HTR2B—thyroid gland—hypothyroidism	0.00316	0.0099	CbGeAlD
Cisapride—CYP2B6—adrenal cortex—hypothyroidism	0.00297	0.00931	CbGeAlD
Cisapride—DRD2—pituitary gland—hypothyroidism	0.00297	0.0093	CbGeAlD
Cisapride—KCNH2—pituitary gland—hypothyroidism	0.00292	0.00916	CbGeAlD
Cisapride—CYP2B6—heart—hypothyroidism	0.00287	0.009	CbGeAlD
Cisapride—CYP2C9—heart—hypothyroidism	0.00284	0.00891	CbGeAlD
Cisapride—CYP2C19—blood—hypothyroidism	0.00274	0.00858	CbGeAlD
Cisapride—CYP2B6—cardiovascular system—hypothyroidism	0.00271	0.00849	CbGeAlD
Cisapride—CYP2C9—cardiovascular system—hypothyroidism	0.00268	0.00841	CbGeAlD
Cisapride—CYP2C8—pituitary gland—hypothyroidism	0.00267	0.00838	CbGeAlD
Cisapride—KCNH2—adrenal gland—hypothyroidism	0.00261	0.00819	CbGeAlD
Cisapride—KCNH2—blood—hypothyroidism	0.00261	0.00819	CbGeAlD
Cisapride—CYP2B6—gonad—hypothyroidism	0.00246	0.00771	CbGeAlD
Cisapride—KCNH2—female gonad—hypothyroidism	0.00243	0.00763	CbGeAlD
Cisapride—CYP2C8—blood—hypothyroidism	0.00239	0.00749	CbGeAlD
Cisapride—HTR2A—heart—hypothyroidism	0.00234	0.00734	CbGeAlD
Cisapride—CYP1A2—blood—hypothyroidism	0.00224	0.00701	CbGeAlD
Cisapride—HTR2A—cardiovascular system—hypothyroidism	0.00221	0.00693	CbGeAlD
Cisapride—DRD2—testis—hypothyroidism	0.00219	0.00687	CbGeAlD
Cisapride—KCNH2—testis—hypothyroidism	0.00216	0.00677	CbGeAlD
Cisapride—CYP1A2—thyroid gland—hypothyroidism	0.00216	0.00676	CbGeAlD
Cisapride—CYP3A5—blood—hypothyroidism	0.00216	0.00676	CbGeAlD
Cisapride—CYP2B6—adrenal gland—hypothyroidism	0.00214	0.00672	CbGeAlD
Cisapride—CYP2B6—blood—hypothyroidism	0.00214	0.00672	CbGeAlD
Cisapride—CYP2C19—liver—hypothyroidism	0.00214	0.00671	CbGeAlD
Cisapride—CYP2C9—blood—hypothyroidism	0.00212	0.00665	CbGeAlD
Cisapride—DRD2—cerebellum—hypothyroidism	0.00202	0.00635	CbGeAlD
Cisapride—CYP3A5—female gonad—hypothyroidism	0.00201	0.0063	CbGeAlD
Cisapride—HTR2A—gonad—hypothyroidism	0.00201	0.00629	CbGeAlD
Cisapride—KCNH2—cerebellum—hypothyroidism	0.00199	0.00625	CbGeAlD
Cisapride—CYP2C8—testis—hypothyroidism	0.00198	0.00619	CbGeAlD
Cisapride—HTR2A—pituitary gland—hypothyroidism	0.00196	0.00613	CbGeAlD
Cisapride—CYP2C8—liver—hypothyroidism	0.00187	0.00586	CbGeAlD
Cisapride—CYP2B6—testis—hypothyroidism	0.00177	0.00556	CbGeAlD
Cisapride—HTR2A—adrenal gland—hypothyroidism	0.00175	0.00548	CbGeAlD
Cisapride—CYP1A2—liver—hypothyroidism	0.00175	0.00548	CbGeAlD
Cisapride—HTR2A—blood—hypothyroidism	0.00175	0.00548	CbGeAlD
Cisapride—CYP3A5—liver—hypothyroidism	0.00169	0.00529	CbGeAlD
Cisapride—CYP2B6—liver—hypothyroidism	0.00168	0.00525	CbGeAlD
Cisapride—CYP2C9—liver—hypothyroidism	0.00166	0.0052	CbGeAlD
Cisapride—CYP3A4—blood—hypothyroidism	0.00162	0.00507	CbGeAlD
Cisapride—CYP2D6—blood—hypothyroidism	0.00159	0.00499	CbGeAlD
Cisapride—CYP2D6—female gonad—hypothyroidism	0.00148	0.00466	CbGeAlD
Cisapride—HTR2A—testis—hypothyroidism	0.00145	0.00453	CbGeAlD
Cisapride—HTR2A—liver—hypothyroidism	0.00137	0.00428	CbGeAlD
Cisapride—HTR2A—cerebellum—hypothyroidism	0.00133	0.00419	CbGeAlD
Cisapride—CYP2D6—testis—hypothyroidism	0.00132	0.00413	CbGeAlD
Cisapride—CYP3A4—liver—hypothyroidism	0.00127	0.00397	CbGeAlD
Cisapride—CYP2D6—liver—hypothyroidism	0.00124	0.0039	CbGeAlD
Cisapride—CYP2D6—cerebellum—hypothyroidism	0.00122	0.00381	CbGeAlD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	9.61e-05	0.00413	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	9.52e-05	0.00409	CbGpPWpGaD
Cisapride—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	9.48e-05	0.00408	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	9.36e-05	0.00403	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CLTC—hypothyroidism	9.1e-05	0.00391	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—TSHB—hypothyroidism	9.07e-05	0.0039	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—TSHR—hypothyroidism	9.07e-05	0.0039	CbGpPWpGaD
Cisapride—HTR4—GPCR ligand binding—POMC—hypothyroidism	9.05e-05	0.00389	CbGpPWpGaD
Cisapride—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	8.85e-05	0.00381	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—AVP—hypothyroidism	8.59e-05	0.00369	CbGpPWpGaD
Cisapride—HTR2C—G alpha (q) signalling events—AVP—hypothyroidism	8.55e-05	0.00368	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	8.48e-05	0.00365	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	8.48e-05	0.00365	CbGpPWpGaD
Cisapride—CYP2B6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	8.47e-05	0.00365	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	8.35e-05	0.00359	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	8.35e-05	0.00359	CbGpPWpGaD
Cisapride—CYP3A5—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	8.28e-05	0.00356	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—TRH—hypothyroidism	8.21e-05	0.00353	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—VAV3—hypothyroidism	7.99e-05	0.00344	CbGpPWpGaD
Cisapride—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	7.9e-05	0.0034	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—TRH—hypothyroidism	7.86e-05	0.00338	CbGpPWpGaD
Cisapride—HTR3A—Transmembrane transport of small molecules—AVP—hypothyroidism	7.72e-05	0.00332	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—AVP—hypothyroidism	7.7e-05	0.00331	CbGpPWpGaD
Cisapride—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	7.65e-05	0.00329	CbGpPWpGaD
Cisapride—HTR2A—G alpha (q) signalling events—AVP—hypothyroidism	7.43e-05	0.0032	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—TSHB—hypothyroidism	7.32e-05	0.00315	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—TSHR—hypothyroidism	7.32e-05	0.00315	CbGpPWpGaD
Cisapride—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	7.26e-05	0.00313	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—VAV3—hypothyroidism	7.26e-05	0.00312	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—TRH—hypothyroidism	7.25e-05	0.00312	CbGpPWpGaD
Cisapride—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	7.2e-05	0.0031	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—IYD—hypothyroidism	7.18e-05	0.00309	CbGpPWpGaD
Cisapride—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.17e-05	0.00309	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—TRH—hypothyroidism	7.13e-05	0.00307	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—AVP—hypothyroidism	7.12e-05	0.00307	CbGpPWpGaD
Cisapride—HTR2B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	7.02e-05	0.00302	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—TSHB—hypothyroidism	7.01e-05	0.00301	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—TSHR—hypothyroidism	7.01e-05	0.00301	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—AVP—hypothyroidism	6.99e-05	0.00301	CbGpPWpGaD
Cisapride—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	6.64e-05	0.00286	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—IYD—hypothyroidism	6.58e-05	0.00283	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—TSHB—hypothyroidism	6.46e-05	0.00278	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—TSHR—hypothyroidism	6.46e-05	0.00278	CbGpPWpGaD
Cisapride—CYP2C19—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	6.4e-05	0.00275	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—TSHR—hypothyroidism	6.36e-05	0.00273	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—TSHB—hypothyroidism	6.36e-05	0.00273	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—SH2B3—hypothyroidism	6.25e-05	0.00269	CbGpPWpGaD
Cisapride—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	6.15e-05	0.00265	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—ATP5O—hypothyroidism	6.11e-05	0.00263	CbGpPWpGaD
Cisapride—CYP3A7—Biological oxidations—POMC—hypothyroidism	6.09e-05	0.00262	CbGpPWpGaD
Cisapride—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.89e-05	0.00253	CbGpPWpGaD
Cisapride—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.84e-05	0.00251	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—TRH—hypothyroidism	5.75e-05	0.00247	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—TPO—hypothyroidism	5.74e-05	0.00247	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	5.66e-05	0.00244	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—ATP5O—hypothyroidism	5.6e-05	0.00241	CbGpPWpGaD
Cisapride—CYP2A6—Biological oxidations—POMC—hypothyroidism	5.58e-05	0.0024	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—AVP—hypothyroidism	5.35e-05	0.0023	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—IYD—hypothyroidism	5.31e-05	0.00228	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—TPO—hypothyroidism	5.26e-05	0.00226	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—TRH—hypothyroidism	5.22e-05	0.00225	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—IYD—hypothyroidism	5.19e-05	0.00223	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—TSHR—hypothyroidism	5.13e-05	0.00221	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—TSHB—hypothyroidism	5.13e-05	0.00221	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—POMC—hypothyroidism	5.12e-05	0.0022	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	5e-05	0.00215	CbGpPWpGaD
Cisapride—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	4.99e-05	0.00215	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	4.92e-05	0.00212	CbGpPWpGaD
Cisapride—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	4.75e-05	0.00204	CbGpPWpGaD
Cisapride—HTR2B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	4.67e-05	0.00201	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—TSHB—hypothyroidism	4.66e-05	0.002	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—TSHR—hypothyroidism	4.66e-05	0.002	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—POMC—hypothyroidism	4.65e-05	0.002	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—TRH—hypothyroidism	4.64e-05	0.002	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—PRL—hypothyroidism	4.63e-05	0.00199	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—ATP5O—hypothyroidism	4.51e-05	0.00194	CbGpPWpGaD
Cisapride—CYP2B6—Biological oxidations—POMC—hypothyroidism	4.5e-05	0.00194	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—IYD—hypothyroidism	4.5e-05	0.00193	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—ATP5O—hypothyroidism	4.41e-05	0.0019	CbGpPWpGaD
Cisapride—CYP3A5—Biological oxidations—POMC—hypothyroidism	4.4e-05	0.00189	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—AVP—hypothyroidism	4.31e-05	0.00186	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—VAV3—hypothyroidism	4.29e-05	0.00184	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—TPO—hypothyroidism	4.24e-05	0.00183	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—TRH—hypothyroidism	4.21e-05	0.00181	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—POMC—hypothyroidism	4.18e-05	0.0018	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—TPO—hypothyroidism	4.15e-05	0.00179	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—TSHB—hypothyroidism	4.14e-05	0.00178	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—TSHR—hypothyroidism	4.14e-05	0.00178	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—AVP—hypothyroidism	4.13e-05	0.00178	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—TRH—hypothyroidism	4.1e-05	0.00176	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—TRH—hypothyroidism	4.03e-05	0.00173	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—IYD—hypothyroidism	4.01e-05	0.00173	CbGpPWpGaD
Cisapride—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	3.85e-05	0.00166	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—ATP5O—hypothyroidism	3.82e-05	0.00164	CbGpPWpGaD
Cisapride—CYP2C8—Biological oxidations—POMC—hypothyroidism	3.81e-05	0.00164	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—AVP—hypothyroidism	3.81e-05	0.00164	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	3.76e-05	0.00162	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—TSHB—hypothyroidism	3.76e-05	0.00162	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—TSHR—hypothyroidism	3.76e-05	0.00162	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—AVP—hypothyroidism	3.75e-05	0.00161	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—TRH—hypothyroidism	3.72e-05	0.0016	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—IYD—hypothyroidism	3.69e-05	0.00159	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—TRH—hypothyroidism	3.66e-05	0.00157	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—IYD—hypothyroidism	3.66e-05	0.00157	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—TSHB—hypothyroidism	3.65e-05	0.00157	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—TSHR—hypothyroidism	3.65e-05	0.00157	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—TPO—hypothyroidism	3.59e-05	0.00155	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—TSHB—hypothyroidism	3.59e-05	0.00155	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—TSHR—hypothyroidism	3.59e-05	0.00155	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CLTC—hypothyroidism	3.57e-05	0.00154	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—POMC—hypothyroidism	3.55e-05	0.00153	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—ATP5O—hypothyroidism	3.41e-05	0.00147	CbGpPWpGaD
Cisapride—CYP2C19—Biological oxidations—POMC—hypothyroidism	3.4e-05	0.00146	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.33e-05	0.00143	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	3.32e-05	0.00143	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—TSHR—hypothyroidism	3.31e-05	0.00143	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—TSHB—hypothyroidism	3.31e-05	0.00143	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	3.27e-05	0.00141	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—TSHB—hypothyroidism	3.26e-05	0.0014	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—TSHR—hypothyroidism	3.26e-05	0.0014	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—TPO—hypothyroidism	3.21e-05	0.00138	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—ATP5O—hypothyroidism	3.14e-05	0.00135	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—VAV3—hypothyroidism	3.14e-05	0.00135	CbGpPWpGaD
Cisapride—CYP2D6—Biological oxidations—POMC—hypothyroidism	3.13e-05	0.00135	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—IYD—hypothyroidism	3.13e-05	0.00135	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—ATP5O—hypothyroidism	3.11e-05	0.00134	CbGpPWpGaD
Cisapride—CYP2C9—Biological oxidations—POMC—hypothyroidism	3.1e-05	0.00133	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TRH—hypothyroidism	3.09e-05	0.00133	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—AVP—hypothyroidism	3.02e-05	0.0013	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	2.97e-05	0.00128	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—TPO—hypothyroidism	2.95e-05	0.00127	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—TPO—hypothyroidism	2.92e-05	0.00126	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CLTC—hypothyroidism	2.88e-05	0.00124	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—POMC—hypothyroidism	2.87e-05	0.00123	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—VAV3—hypothyroidism	2.85e-05	0.00123	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TSHB—hypothyroidism	2.75e-05	0.00118	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TSHR—hypothyroidism	2.75e-05	0.00118	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—POMC—hypothyroidism	2.74e-05	0.00118	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—AVP—hypothyroidism	2.74e-05	0.00118	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	2.71e-05	0.00117	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—ATP5O—hypothyroidism	2.66e-05	0.00114	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—TSHB—hypothyroidism	2.66e-05	0.00114	CbGpPWpGaD
Cisapride—CYP1A2—Biological oxidations—POMC—hypothyroidism	2.65e-05	0.00114	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—IGF1—hypothyroidism	2.64e-05	0.00114	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CLTC—hypothyroidism	2.54e-05	0.00109	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—VAV3—hypothyroidism	2.53e-05	0.00109	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—POMC—hypothyroidism	2.53e-05	0.00109	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CLTC—hypothyroidism	2.5e-05	0.00108	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—TPO—hypothyroidism	2.5e-05	0.00108	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TRH—hypothyroidism	2.49e-05	0.00107	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—POMC—hypothyroidism	2.49e-05	0.00107	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—SH2B3—hypothyroidism	2.45e-05	0.00105	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—AVP—hypothyroidism	2.44e-05	0.00105	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—TSHB—hypothyroidism	2.44e-05	0.00105	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—IYD—hypothyroidism	2.41e-05	0.00104	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—PIK3C2A—hypothyroidism	2.37e-05	0.00102	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	2.32e-05	0.000996	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—VAV3—hypothyroidism	2.3e-05	0.000988	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—VAV3—hypothyroidism	2.23e-05	0.000961	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TSHB—hypothyroidism	2.22e-05	0.000955	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TSHR—hypothyroidism	2.22e-05	0.000955	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—AVP—hypothyroidism	2.21e-05	0.000952	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—VAV3—hypothyroidism	2.2e-05	0.000945	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TRH—hypothyroidism	2.2e-05	0.000945	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—PIK3C2A—hypothyroidism	2.17e-05	0.000934	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TRH—hypothyroidism	2.16e-05	0.00093	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—AVP—hypothyroidism	2.15e-05	0.000926	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—AVP—hypothyroidism	2.12e-05	0.000911	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.05e-05	0.000883	CbGpPWpGaD
Cisapride—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.05e-05	0.00088	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—VAV3—hypothyroidism	2.03e-05	0.000872	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—POMC—hypothyroidism	2.01e-05	0.000864	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—VAV3—hypothyroidism	2e-05	0.000858	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—SLC5A5—hypothyroidism	1.99e-05	0.000856	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—SH2B3—hypothyroidism	1.98e-05	0.000851	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—TSHB—hypothyroidism	1.97e-05	0.000846	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TSHR—hypothyroidism	1.96e-05	0.000842	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TSHB—hypothyroidism	1.96e-05	0.000842	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—AVP—hypothyroidism	1.95e-05	0.00084	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—TPO—hypothyroidism	1.93e-05	0.00083	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TSHB—hypothyroidism	1.93e-05	0.000829	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TSHR—hypothyroidism	1.93e-05	0.000829	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—AVP—hypothyroidism	1.92e-05	0.000827	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—TSHB—hypothyroidism	1.92e-05	0.000826	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—SLC5A5—hypothyroidism	1.82e-05	0.000784	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—POMC—hypothyroidism	1.82e-05	0.000784	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—PRL—hypothyroidism	1.82e-05	0.000782	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—PIK3C2A—hypothyroidism	1.75e-05	0.000754	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—SH2B3—hypothyroidism	1.75e-05	0.000751	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—SH2B3—hypothyroidism	1.72e-05	0.000739	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	1.71e-05	0.000737	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—VAV3—hypothyroidism	1.68e-05	0.000724	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—TSHB—hypothyroidism	1.66e-05	0.000716	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—AVP—hypothyroidism	1.62e-05	0.000697	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—POMC—hypothyroidism	1.62e-05	0.000697	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—TSHB—hypothyroidism	1.49e-05	0.000639	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	1.48e-05	0.000638	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—SLC5A5—hypothyroidism	1.47e-05	0.000633	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—POMC—hypothyroidism	1.47e-05	0.000633	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—PRL—hypothyroidism	1.47e-05	0.000631	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.46e-05	0.00063	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—SLC5A5—hypothyroidism	1.44e-05	0.000619	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—POMC—hypothyroidism	1.43e-05	0.000615	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—POMC—hypothyroidism	1.41e-05	0.000605	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—TSHB—hypothyroidism	1.37e-05	0.000588	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—VAV3—hypothyroidism	1.36e-05	0.000584	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—TSHB—hypothyroidism	1.35e-05	0.000583	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	1.32e-05	0.000569	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—AVP—hypothyroidism	1.31e-05	0.000563	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.31e-05	0.000562	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—POMC—hypothyroidism	1.3e-05	0.000559	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—PRL—hypothyroidism	1.29e-05	0.000557	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—POMC—hypothyroidism	1.28e-05	0.00055	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—PRL—hypothyroidism	1.27e-05	0.000548	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—SLC5A5—hypothyroidism	1.25e-05	0.000536	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	1.22e-05	0.000524	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	1.21e-05	0.000519	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—VAV3—hypothyroidism	1.2e-05	0.000515	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.19e-05	0.000512	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—VAV3—hypothyroidism	1.18e-05	0.000507	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—TSHB—hypothyroidism	1.16e-05	0.000498	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—AVP—hypothyroidism	1.15e-05	0.000496	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—AVP—hypothyroidism	1.14e-05	0.000489	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—SLC5A5—hypothyroidism	1.11e-05	0.000478	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—POMC—hypothyroidism	1.08e-05	0.000463	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—POMC—hypothyroidism	1.04e-05	0.000448	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—IGF1—hypothyroidism	1.04e-05	0.000446	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	1.03e-05	0.000444	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—SLC5A5—hypothyroidism	1.02e-05	0.00044	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.02e-05	0.000438	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—SLC5A5—hypothyroidism	1.01e-05	0.000436	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—POMC—hypothyroidism	9.54e-06	0.00041	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—TSHB—hypothyroidism	8.93e-06	0.000384	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—POMC—hypothyroidism	8.69e-06	0.000374	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—SLC5A5—hypothyroidism	8.66e-06	0.000373	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—IGF1—hypothyroidism	8.36e-06	0.00036	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	7.96e-06	0.000342	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—POMC—hypothyroidism	7.7e-06	0.000331	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—POMC—hypothyroidism	7.67e-06	0.00033	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—POMC—hypothyroidism	7.55e-06	0.000325	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—POMC—hypothyroidism	7.52e-06	0.000324	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—IGF1—hypothyroidism	7.38e-06	0.000317	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—IGF1—hypothyroidism	7.26e-06	0.000312	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—SLC5A5—hypothyroidism	6.69e-06	0.000288	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—POMC—hypothyroidism	6.52e-06	0.00028	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—POMC—hypothyroidism	5.82e-06	0.00025	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—POMC—hypothyroidism	5.35e-06	0.00023	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—POMC—hypothyroidism	5.3e-06	0.000228	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—POMC—hypothyroidism	4.53e-06	0.000195	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—POMC—hypothyroidism	3.5e-06	0.00015	CbGpPWpGaD
